AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

RECCE PHARMACEUTICALS LTD

0.290

+0.000

Volume:92.67K

Turnover:26.75K

Market Cap:72.42M

PE:-3.16

High:0.290

Open:0.285

Low:0.280

Close:0.290

Loading ...

Overview Company News Filings

Recce Pharmaceuticals Obtains Australian Patent for Anti-Infectives

MT Newswires Live

BRIEF-Recce Pharmaceuticals Says Australia Patent Granted For Recce Anti-Infectives

Recce Pharmaceuticals Ltd-Australia Patent Granted for Recce Anti-Infectives

THOMSON REUTERS

Recce scores $6.75M R&D rebate

The Market Herald

BRIEF-Recce Pharmaceuticals Receives Ethics Approval In Indonesia To Commence Registrational Phase 3 Trial Of Recce 327 Topical Gel In Diabetic Foot Infections

Recce Pharmaceuticals Secures Ethics Approval in Indonesia for Diabetic Foot Ulcer Trial

MT Newswires Live

BRIEF-Recce Pharmaceuticals Says Ethics Approval For Registrational Ph3 R327g Clinical Trial

Recce Pharmaceuticals Ltd-Ethics Approval for Registrational Ph3 R327g Clinical Trial

THOMSON REUTERS

BRIEF-Recce Pharmaceuticals Advances Patient Dosing To Final Stages In Phase II Trial

Recce Pharmaceuticals Ltd - All Patients Dosed Met Primary Endpoints With R327g

THOMSON REUTERS

Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase Ii Trial for Acute Bacterial Skin and Skin Structure Infections

THOMSON REUTERS

Recce Pharmaceuticals Ltd - Patient Dosing on Track to Be Completed by End of 2024

THOMSON REUTERS

Recce Pharmaceuticals Ltd - Strong Therapeutic Response With R327g, No Serious Adverse Events Reported

THOMSON REUTERS

Recce Pharmaceuticals Nears Completion of Second Phase Trial for Topical Therapy

MT Newswires Live

ASX Market Close: RBA keeps rates on hold amid sticky inflation | November 5, 2024

The Market Herald

Recce Pharmaceuticals Ltd - No Serious Adverse Events Noted, Trial to Continue

THOMSON REUTERS

Recce Pharmaceuticals Announces Interim Efficacy Data and Safety Approval for Phase Ii Absssi Clinical Trial

THOMSON REUTERS

Recce Pharmaceuticals Ltd - 327 Gel Demonstrated Safe and Well-Tolerated in Patients

THOMSON REUTERS

Recce Pharmaceuticals Ltd - All Patients Met Primary Endpoint With R327g

THOMSON REUTERS

Investors push Recce Pharmaceuticals (ASX:RCE) 13% lower this week, company's increasing losses might be to blame

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RCE.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.29,"timestamp":1745475120000,"preClose":0.29,"halted":0,"volume":92674,"delay":0,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":167272518,"shares":249728760,"eps":-0.091765,"marketStatus":"Market Closed","change":0,"latestTime":"04-24 16:12:00 AEST","open":0.285,"high":0.29,"low":0.28,"amount":26745,"amplitude":0.034483,"askPrice":0.29,"askSize":63653,"bidPrice":0.28,"bidSize":131092,"shortable":3,"etf":0,"ttmEps":-0.091765,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745798400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.29,"openAndCloseTimeList":[[1745452800000,1745474400000]],"volumeRatio":0.5204539043732951,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","floatShares":167272518,"roa":"-217.58%","roe":"-1277.62%","lyrEps":-0.099727,"volumeRatio":0.5204539043732951,"shares":249728760,"dividePrice":0,"high":0.29,"amplitude":0.034483,"preClose":0.29,"low":0.28,"week52Low":0.275,"pbRate":"-14.52","psRate":"7.55","week52High":0.688,"institutionHeld":0,"latestPrice":0.29,"committee":0.346294,"eps":-0.091765,"divideRate":0,"volume":92674,"delay":0,"ttmEps":-0.091765,"open":0.285,"prevYearClose":0.48,"prevWeekClose":0.29,"prevMonthClose":0.357,"prevQuarterClose":0.357,"fiveDayClose":0.29,"twentyDayClose":0.362,"sixtyDayClose":0.461},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCE.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2486154064","title":"Recce Pharmaceuticals Obtains Australian Patent for Anti-Infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2486154064","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486154064?lang=en_us&edition=fundamental","pubTime":"2024-11-26 06:59","pubTimestamp":1732575595,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals (ASX:RCE) obtained Patent Family 3 in Australia for its R327 and R529 anti-infectives, effective until 2037, according to a Tuesday filing with the Australian bourse.The pharmaceutical company said it is now patent-protected in all major pharmaceutical markets globally.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XAO.AU","BK7096","RCE.AU","XJO.AU"],"gpt_icon":0},{"id":"2486066608","title":"BRIEF-Recce Pharmaceuticals Says Australia Patent Granted For Recce Anti-Infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2486066608","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486066608?lang=en_us&edition=fundamental","pubTime":"2024-11-26 06:04","pubTimestamp":1732572289,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Says Australia Patent Granted For Recce Anti-InfectivesNov 26 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:AUSTRALIA PATENT GRANTED FOR RECCE ANTI-INFECTIVESFurther company coverage: RCE.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nTUE9CD3T3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","XJO.AU","XAO.AU","XKO.AU","RCE.AU"],"gpt_icon":0},{"id":"2486063148","title":"Recce Pharmaceuticals Ltd-Australia Patent Granted for Recce Anti-Infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2486063148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486063148?lang=en_us&edition=fundamental","pubTime":"2024-11-26 05:37","pubTimestamp":1732570666,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nTUE9CD3T3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2483127868","title":"Recce scores $6.75M R&D rebate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483127868","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483127868?lang=en_us&edition=fundamental","pubTime":"2024-11-14 13:29","pubTimestamp":1731562140,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  has received a $6.75 million Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for FY24.This receipt was used to repay advances from Endpoints Capital reflecting R&D rebate credits for FY24.The Company is developing a new class of Synthetic Anti-infectives and the injection of funds reflects R&D activities undertaken locally and overseas.The Australian Government’s 43.5% Research & Development Tax Incentive rebate is intended to incentivise companies to develop new innovative solutions onshore.“We are delighted to receive this substantial R&D Tax Incentive rebate, which underscores the Australian Government’s strong support for innovation in life sciences,” Recce CEO James Graham said.“This funding strengthens our ability to drive forward our R&D initiatives both domestically and internationally, accelerating our missionto develop cutting-edge anti-infective solutions.“By leveraging this rebate, we continue to push the bounda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/recce-scores-6-75m-r-d-rebate-2024-11-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["XAO.AU","XJO.AU","BK7096","XKO.AU","RCE.AU"],"gpt_icon":0},{"id":"2482570434","title":"BRIEF-Recce Pharmaceuticals Receives Ethics Approval In Indonesia To Commence Registrational Phase 3 Trial Of Recce 327 Topical Gel In Diabetic Foot Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2482570434","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482570434?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:21","pubTimestamp":1731417702,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - Recce Pharmaceuticals Ltd   :   * RECCE PHARMACEUTICALS RECEIVES ETHICS APPROVAL IN INDONESIA TO COMMENCE REGISTRATIONAL PHASE 3 TRIAL OF RECCE® 327 TOPICAL GEL IN DIABETIC FOOT INFECTIONSSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2482220616","title":"Recce Pharmaceuticals Secures Ethics Approval in Indonesia for Diabetic Foot Ulcer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482220616","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482220616?lang=en_us&edition=fundamental","pubTime":"2024-11-11 15:03","pubTimestamp":1731308608,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  secured approval from the Human Research Ethics Committee to investigate the use of the Recce 327 topical gel in a phase 3 trial in patients with diabetic foot ulcers, according to a Monday filing with the Australian bourse.The receipt of the approval means the company met the safety and efficacy testing required to proceed with the large-scale trial.The 12-month trial will be conducted in Indonesia, with regulatory submission anticipated for late 2025, the filing said.The company's shares closed up more than 3% Monday.Price : $0.49, Change: $+0.02, Percent Change: +3.19%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1043141123.HKD","BK7096","RCE.AU","BK4125","LU2238339852.HKD","LU0345774631.USD","LU0426412945.USD","AUD","LU0994945656.USD","LU0426417589.USD"],"gpt_icon":0},{"id":"2482429012","title":"BRIEF-Recce Pharmaceuticals Says Ethics Approval For Registrational Ph3 R327g Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482429012","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482429012?lang=en_us&edition=fundamental","pubTime":"2024-11-11 06:17","pubTimestamp":1731277041,"startTime":"0","endTime":"0","summary":"Nov 11 (Reuters) - Recce Pharmaceuticals   :   * ETHICS APPROVAL FOR REGISTRATIONAL PH3 R327G CLINICAL TRIALFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2482290140","title":"Recce Pharmaceuticals Ltd-Ethics Approval for Registrational Ph3 R327g Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482290140","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482290140?lang=en_us&edition=fundamental","pubTime":"2024-11-11 06:16","pubTimestamp":1731276981,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241110:nTUE8QGSLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2481609735","title":"BRIEF-Recce Pharmaceuticals Advances Patient Dosing To Final Stages In Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2481609735","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481609735?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:22","pubTimestamp":1730899362,"startTime":"0","endTime":"0","summary":"Nov 6  - Recce Pharmaceuticals Ltd   :   * RECCE PHARMACEUTICALS ADVANCES PATIENT DOSING TO FINAL STAGES IN PHASE II TRIAL FOR ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS   * RECCE PHARMACEUTICALS LTD - PATIENT DOSING ON TRACK TO BE COMPLETED BY END OF 2024   * RECCE PHARMACEUTICALS LTD - ALL PATIENTS DOSED MET PRIMARY ENDPOINTS WITH R327G   * RECCE PHARMACEUTICALS LTD - STRONG THERAPEUTIC RESPONSE WITH R327G, NO SERIOUS ADVERSE EVENTS REPORTEDSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2481997606","title":"Recce Pharmaceuticals Ltd - All Patients Dosed Met Primary Endpoints With R327g","url":"https://stock-news.laohu8.com/highlight/detail?id=2481997606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481997606?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:00","pubTimestamp":1730898002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUA8WPH83:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2481960682","title":"Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase Ii Trial for Acute Bacterial Skin and Skin Structure Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2481960682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481960682?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:00","pubTimestamp":1730898002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUA8WPH83:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2481960651","title":"Recce Pharmaceuticals Ltd - Patient Dosing on Track to Be Completed by End of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481960651","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481960651?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:00","pubTimestamp":1730898002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUA8WPH83:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2481606967","title":"Recce Pharmaceuticals Ltd - Strong Therapeutic Response With R327g, No Serious Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2481606967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481606967?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:00","pubTimestamp":1730898002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUA8WPH83:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2481694899","title":"Recce Pharmaceuticals Nears Completion of Second Phase Trial for Topical Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2481694899","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481694899?lang=en_us&edition=fundamental","pubTime":"2024-11-06 10:21","pubTimestamp":1730859703,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  said it is nearing the completion of its second phase clinical trial of RECCE 327 Topical Gel , targeting acute bacterial skin and skin structure infections, with 20 out of 30 patients dosed, according to a Tuesday filing with the Australian bourse.The study showed that all patients who completed R327G treatment met the primary endpoints of the study, either cured or with notable improvement, with no reported serious adverse events, the filing said.The patient dosing is expected to be completed within the year, according to the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2481543313","title":"ASX Market Close: RBA keeps rates on hold amid sticky inflation | November 5, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481543313","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481543313?lang=en_us&edition=fundamental","pubTime":"2024-11-05 13:54","pubTimestamp":1730786040,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.4% at 8,131 points.The Reserve Bank Board has kept interest rates on hold at 4.35% in line with consensus expectations. RBA Governor Michelle Bullock says the bank wants to be more convinced inflation is going to be back in the target band.All sectors lost ground and Utilities was the worst performer, down 0.7%, followed closely by Financials, down 0.6%, and Health Care and Staples, both down 0.55%.Peppermint Innovation closed flat on a new funding agreement to bolster its digital growth strategy and financial inclusion efforts in the Philippines. The company secured up to $3 million through convertible notes from Obsidian Global.Recce Pharmaceutical Ltd closed up 4.49% after reaching a milestone in its Phase II clinical trial to test the efficacy of its topical gel for treatment of Acute Bacterial Skin and Skin Structure Infections.Augustus Minerals  closed flat on news its acquiring a gold project in WA ripe for exploration and near several functioning mines.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-rba-keeps-rates-on-hold-amid-sticky-inflation-november-5-2024-2024-11-05/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["PIL.AU","RCE.AU","BK7016","BK7083","BK7041","BK7095","BK7153","PDN.AU","BK7509","PYC.AU","AUG.AU","BK7096","BK7067","HVN.AU"],"gpt_icon":0},{"id":"2479835180","title":"Recce Pharmaceuticals Ltd - No Serious Adverse Events Noted, Trial to Continue","url":"https://stock-news.laohu8.com/highlight/detail?id=2479835180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479835180?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:00","pubTimestamp":1730376000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUA4FFLCV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2479778088","title":"Recce Pharmaceuticals Announces Interim Efficacy Data and Safety Approval for Phase Ii Absssi Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2479778088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479778088?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:00","pubTimestamp":1730376000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUA4FFLCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2479083512","title":"Recce Pharmaceuticals Ltd - 327 Gel Demonstrated Safe and Well-Tolerated in Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2479083512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479083512?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:00","pubTimestamp":1730376000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUA4FFLCV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2479083350","title":"Recce Pharmaceuticals Ltd - All Patients Met Primary Endpoint With R327g","url":"https://stock-news.laohu8.com/highlight/detail?id=2479083350","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479083350?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:00","pubTimestamp":1730376000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUA4FFLCV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2479964722","title":"Investors push Recce Pharmaceuticals (ASX:RCE) 13% lower this week, company's increasing losses might be to blame","url":"https://stock-news.laohu8.com/highlight/detail?id=2479964722","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479964722?lang=en_us&edition=fundamental","pubTime":"2024-10-30 04:51","pubTimestamp":1730235079,"startTime":"0","endTime":"0","summary":"The Recce Pharmaceuticals Ltd ( ASX:RCE ) share price has had a bad week, falling 13%. On the other hand the returns...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rce/recce-pharmaceuticals-shares/news/investors-push-recce-pharmaceuticals-asxrce-13-lower-this-we","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RCE.AU","ISBC","BK4211","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":62,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCE.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-04-15","symbol":"RCE.AU","defaultRemindTime":1744675200000,"type":"split","dateTimestamp":1744639200000,"forFactor":990476,"toFactor":1000000,"ratio":0.990476}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCE.AU\",market:\"AU\",,,undefined,":[]}}